Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course tenofovir/emtricitabine for viral clearance in non-hospitalized COVID-19 patients
2020-001867-94Phase 3Terminated
- Sponsor
- CHU Caen Normandie
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of emtricitabine + tenofovir disoproxil in coronavirus disease 2019 (COVID-19), sponsored by CHU Caen Normandie. Primary endpoint: Nasopharyngeal SARS-CoV-2 PCR negativity at day 4. Started Apr 2020; status: terminated.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001867-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001867-94.